

杜仲中的一个新环烯醚萜类化合物

周诗琪^{1,2}, 郝志友^{1,2}, 杨 梦^{1,2}, 肖超远^{1,2}, 张俊阳^{1,2}, 张博文^{1,2}, 陶思琦^{1,2},
郑晓珂^{1,2}, 冯卫生^{1,2,3*}

(1. 河南中医药大学药学院, 河南 郑州 450046; 2. 河南省中药开发工程技术研究中心, 河南 郑州 450046;
3. 呼吸疾病中医药防治省部共建协同创新中心, 河南 郑州 450046)

摘要: 利用硅胶、Sephadex LH-20 和 Toyopearl HW-40C 等柱色谱及半制备液相等分离纯化方法, 从杜仲中分离得到 11 个化合物。运用现代波谱学方法确定化合物的结构, 分别鉴定为 neoeucommiate A (**1**)、(7*S*, 8*R*)-dihydrodehydrodiconiferyl alcohol (**2**)、urolignoside (**3**)、ficusal (**4**)、tiruneesiin (**5**)、glochidioboside (**6**)、forsythialansides B (**7**)、ecdysanol B (**8**)、(+)-syringaresinol-4-*O*- β -*D*-glucopyranoside (**9**)、(+)-pinoresinol-4-*O*-[6''-*O*-vanilloyl]- β -*D*-glucopyranoside (**10**) 和 samsesquinoside (**11**)。其中化合物 **1** 为新化合物, 化合物 **3**~**7**、**10**、**11** 为首次从杜仲中分离得到。

关键词: 杜仲; neoeucommiate A; 环烯醚萜; 木脂素; 化学成分

中图分类号: R284 文献标识码: A 文章编号: 0513-4870(2024)07-2062-07

A new iridoid from *Eucommia ulmoides*

ZHOU Shi-qi^{1,2}, HAO Zhi-you^{1,2}, YANG Meng^{1,2}, XIAO Chao-yuan^{1,2}, ZHANG Jun-yang^{1,2},
ZHANG Bo-wen^{1,2}, TAO Si-qi^{1,2}, ZHENG Xiao-ke^{1,2}, FENG Wei-sheng^{1,2,3*}

(1. School of Pharmacy, Henan University of Chinese Medicine, Zhengzhou 450046, China; 2. The Engineering and Technology Research Center for Chinese Medicine Development of Henan Province, Zhengzhou 450046, China;
3. Co-construction of Collaborative Innovation Center for Chinese Medicine and Respiratory Diseases by Henan & Education Ministry, Zhengzhou 450046, China)

Abstract: Eleven compounds were isolated from *Eucommia ulmoides* by silica gel, Sephadex LH-20, HW-40C column chromatography and semi-preparative HPLC. Their structures were identified by modern spectroscopic methods as neoeucommiate A (**1**), (7*S*, 8*R*)-dihydrodehydrodiconiferyl alcohol (**2**), urolignoside (**3**), ficusal (**4**), tiruneesiin (**5**), glochidioboside (**6**), forsythialansides B (**7**), ecdysanol B (**8**), (+)-syringaresinol-4-*O*- β -*D*-glucopyranoside (**9**), (+)-pinoresinol 4-*O*-[6''-*O*-vanilloyl]- β -*D*-glucopyranoside (**10**), samsesquinoside (**11**). Compound **1** is a new compound, compounds **3**–**7**, **10** and **11** were isolated from *Eucommia ulmoides* for the first time.

Key words: *Eucommia*; neoeucommiate A; iridoids; lignans; chemical composition

杜仲 (*Eucommia ulmoides* Oliv.), 又名思仙、木棉、思仲等, 为单科单属种植物, 是我国特有的经济树种, 广泛分布于河南、四川、湖南、贵州、云南等省^[1]。杜仲

来源于杜仲的干燥树皮, 《神农本草经》将其列为上品, 味甘, 性温。归肝、肾经, 具有补肝肾、强筋骨、安胎的功效, 常用于肝肾不足、腰膝酸痛、筋骨无力、头晕目眩、妊娠漏血、胎动不安等症^[2]。杜仲的现代药理活性主要表现为抗骨质疏松、抗炎、神经保护、降血压、降血糖等^[3]。现有研究表明, 杜仲的化学成分主要有木脂素类、环烯醚萜类、黄酮类、酚类、三萜类及甾体类

收稿日期: 2023-12-17; 修回日期: 2024-01-02.

基金项目: 中央引导地方科技发展专项资金 ([2016]149); 河南省高层次人才特殊支持计划 (ZYQR201810080).

*通讯作者 Tel / Fax: 86-371-60190296, E-mail: fwsh@hactcm.edu.cn

DOI: 10.16438/j.0513-4870.2023-1408

等^[4]。近年来, 杜仲作为一种药食同源资源, 其叶、籽、雄花等部分已开发成多种保健品及食品原料^[5], 极大丰富了杜仲的应用价值, 其巨大的开发前景也引起了社会广泛关注。为了进一步了解杜仲的化学成分, 本实验以杜仲为研究对象, 对其进行系统的化学成分研究, 从中分离得到了1个环烯醚萜类化合物, 10个木脂素类化合物, 结构见图1。化合物**1**为新化合物, 化合物**3**~**7**、**10**、**11**为首次从杜仲中分离得到。

结果与讨论

1 结构鉴定

化合物**1**为淡黄色油状物, $[\alpha]_D^{20} +89.196$ (*c* 0.084, CH₃OH); UV在202 nm处有最大吸收; IR光谱显示出酯羰基(1 793 cm⁻¹)吸收; HR-ESI-MS给出其准分子离子峰 *m/z* 283.117 6 [M+H]⁺ (calcd for C₁₄H₁₉O₆, 283.117 6), 提示化合物**1**的分子式为C₁₄H₁₈O₆, 计算不饱和度为6。¹H NMR谱中(500 MHz, DMSO-*d*₆)谱中, 在 δ_H 5.71 (1H, s, H-7)出现烯氢质子信号, δ_H 4.65 (1H, m, H-10a), 4.61 (1H, d, *J* = 13.5 Hz, H-10b), 4.40 (1H, dd, *J* = 12.5, 4.0 Hz, H-1a), 4.35 (1H, m, H-1b), 4.30 (1H, dd, *J* = 11.5, 6.0 Hz, H-11a), 4.03 (1H, dd, *J* = 11.5, 7.5 Hz, H-11b)为3个连氧亚甲基的氢质子信号, δ_H 3.28 (1H, m,

H-4), 3.18 (1H, m, H-9), 3.12 (1H, m, H-5)为3个次甲基的氢质子信号, δ_H 2.03 (3H, s, H-15), 2.03 (3H, s, H-13)为2个甲基的氢质子信号, δ_H 2.42 (1H, m, H-6a), 1.90 (1H, m, H-6b)为1个亚甲基的氢质子信号。分析¹³C NMR(125 MHz, DMSO-*d*₆)谱并结合DEPT-135和HSQC谱可知, 化合物**1**中共有14个碳, 其中 δ_C 172.6 (C-3), 170.2 (C-12), 170.1 (C-14)为3个羰基碳信号, δ_C 137.1 (C-8), 129.9 (C-7)为一组双键的碳信号, δ_C 66.5 (C-1), 61.1 (C-11), 60.5 (C-10)为3个连氧亚甲基的碳信号, δ_C 44.5 (C-9), 40.6 (C-4), 34.3 (C-6), 33.9 (C-5)为1个亚甲基和3个次甲基的碳信号, δ_C 20.3 (C-13, 15)为两个甲基的碳信号。¹H-¹H COSY谱中(图2)显示H-9(δ_H 3.18)与H-1(δ_H 4.40, 4.35)和H-5(δ_H 3.12)的相关信号, 说明该结构中含有一个-O-CH₂-CH-CH-的结构片段, H-6(δ_H 2.42, 1.90)与H-7(δ_H 5.71)和H-5(δ_H 3.12)具有相关、H-4(δ_H 3.28)与H-11(δ_H 4.30, 4.03)和H-5(δ_H 3.12)具有相关, 推测结构中含有一个-C=CH-CH₂-CH-CH-CH₂-O-的结构片段。

在HMBC谱(图2)中, H-11(δ_H 4.30, 4.03)与C-3(δ_C 172.6)、C-12(δ_C 170.2)具有远程相关, H-13(δ_H 2.03)与C-12(δ_C 170.2)有远程相关, H-1(δ_H 4.40, 4.35)与C-3(δ_C 172.6)、C-5(δ_C 33.9)具有远程相关, 提示结




Figure 1 Structures of compound 1-11




Figure 2 Structure of compound **1** and its key ^1H - ^1H COSY, HMBC, and NOESY correlations

构中含有一个六元氧杂环和一个 $\text{CH}_3\text{-CO-O-CH}_2\text{-}$ 的结构片段。H-1 (δ_{H} 4.40, 4.35) 与 C-8 (δ_{C} 137.1)、C-5 (δ_{C} 33.9) 具有远程相关, 提示结构中含有一个不饱和五元环并与六元氧杂环相连。H-10 (δ_{H} 4.65, 4.61) 与 C-14 (δ_{C} 170.1)、C-7 (δ_{C} 129.9) 具有远程相关, H-15 (δ_{H} 2.03) 与 C-14 (δ_{C} 170.1) 有远程相关, 提示结构中含有另一个 $\text{CH}_3\text{-CO-O-CH}_2\text{-}$ 的结构片段与 C-8 (δ_{C} 137.1) 相连。

化合物 **1** 的相对构型通过 NOESY 谱确定, 在 NOESY 谱中 (图 2), H-4 和 H-9 与 H-1a 相关, H-5 和 H-9 与 H-6a 相关, 确定 H-4、H-5 和 H-9 在同侧。化合物 **1** 的绝对构型通过电子圆二色性计算与实验 ECD 对比来确定, 在 TDDFT/B3LYP/6-31G(d,p) 水平下使用 SMD 模式并添加色散校正计算。结果显示实验 ECD 曲线与构型为 (4*R*,5*S*,9*S*) 的曲线吻合较好 (图 3)。最终确定化合物 **1** 的结构得到确定, 命名为 neoeucommiate A。




Figure 3 Calculated and experimental ECD spectra of compound **1**

2 讨论

本研究从杜仲中分离得到 1 个环烯醚萜类化合物, 10 个木脂素类化合物, 其中木脂素类化合物结构涉及苯并呋喃型木脂素、单环氧木脂素和双环氧木脂素, 1 个环烯醚萜类化合物为新化合物, 7 个木脂素类化合物为首次从杜仲中分离得到, 进一步丰富了杜仲的化学成分。前期研究报道杜仲在抗炎、抗肿瘤及抗氧化方面具有一定的药理活性, 化合物 **2**、**9**~**11** 具有较显著的抗氧化活性^[6]; 化合物 **3**、**8** 具有较显著的抗炎

活性^[7], 化合物 **6** 能诱导真菌细胞凋亡^[8]; 化合物 **10** 对 PANC-1 人胰腺癌细胞系具有细胞毒性^[9]。

综上所述, 本研究丰富了杜仲的化学成分, 为探究杜仲的药效物质基础提供科学依据。

实验部分

Bruker AVANCE III 500 型核磁共振仪 (TMS 内标) 和 Bruker maxis HD 型飞行时间质谱 (德国布鲁克公司); Thermo EVO300 型紫外分光光度计和 Thermo Nicolet IS 10 傅里叶变换红外光谱仪 (美国 Thermo Scientific 公司); Chirascan qCD 圆二色光谱仪 (英国 Applied Photophysics 公司); Autopol IV 全自动旋光仪 (美国鲁道夫公司); 赛谱锐思 LC-52 型高压制备液相色谱仪 (赛谱锐思北京科技有限公司); N-1111 型冷冻水循环装置和 N-1001 型旋转蒸发仪 (上海埃朗仪器有限公司); 柱色谱填料 Sephadex LH-20 (GE Healthcare 公司); COSMOSIL 5C18-MS-II 色谱柱 (250 mm × 10 mm, 5 μm; 日本 Nacalai Tesque 公司); MCI gel CHP-20、Diaion HP-20 大孔吸附树脂 (日本三菱化学公司); Toyopearl HW-40C (日本 TOSOH 公司); 柱色谱硅胶 (100~200 和 200~300 目, 青岛海洋化工厂); 甲醇、乙腈 (色谱纯, 天津市富宇精细化工有限公司)。

杜仲药材购自安徽亳州药材市场, 经河南中医药大学董诚明教授鉴定为杜仲科杜仲属植物杜仲 (*Eucommia ulmoides* Oliv.) 的干燥树皮, 药材标本 (NO.20210603) 保存于河南省中药开发工程技术研究中心。

1 提取分离

杜仲的干燥树皮 (50 kg) 粉碎成粗颗粒, 用 95% 乙醇回流提取 3 次, 减压浓缩得到浸膏。浸膏加适量水分散, 依次用石油醚、乙酸乙酯、正丁醇萃取, 得到石油醚部位 (600.5 g)、乙酸乙酯部位 (2.0 kg)、正丁醇部位 (260.4 g)。

乙酸乙酯部位 (2.0 kg) 用硅胶柱色谱分离, 并用石油醚-丙酮 (50:1→1:1) 进行梯度洗脱, 得到 A~H 共 8 个组分。对组分 E (467.0 g) 进行硅胶柱色谱分离, 先以石油醚-丙酮 (200:1→20:1) 进行梯度洗脱, 再用二氯甲烷-甲醇 (200:1→1:1) 进行梯度洗脱, 通过 TLC 检识合并相同流分得到 5 个组分, 即 Fr.1~Fr.5。对 Fr.1 (60.3 g) 用硅胶柱色谱分离, 用石油醚-乙酸乙酯 (40:1→1:1) 进行梯度洗脱, 通过 TLC 检识合并相同流分得到 9 个组分, 即 Fr.1-1~Fr.1-9。Fr.1-9 (6.5 g) 经 MCI 柱色谱分离, 用甲醇-水 (30:70→100:0) 进行梯度洗脱, 通过 TLC 检识合并相同流分得到 11 个组分, 即 Fr.1-9-1~Fr.1-9-11。Fr.1-9-7 (1.1 g) 经半制备

液相色谱(乙腈-水, 21:79)等度洗脱, 得到化合物**1** ($t_R = 53.0$ min, 3.2 mg)。Fr.1-9-10 (837.6 mg) 经半制备液相色谱(甲醇-水, 58:42)等度洗脱, 得到化合物**5** ($t_R = 43.3$ min, 2.0 mg)。

正丁醇部位(260.4 g)上大孔吸附树脂柱Diaion HP-20, 依次用水、20%乙醇、40%乙醇、60%乙醇、80%乙醇、95%乙醇进行梯度洗脱, 对40%乙醇部位(85.0 g)上硅胶柱色谱分离, 用二氯甲烷-甲醇(50:1→1:1)进行梯度洗脱, 通过TLC检识合并相同流分得到13个组分, 即D4-1~D4-13。D4-2 (2.8 g) 经Sephadex LH-20凝胶柱色谱分离, 用甲醇进行等度洗脱, 经TLC检识合并相同流分得到4个组分, 即D4-2-1~D4-2-4。D4-2-3 (750.3 mg) 经半制备液相色谱(甲醇-水, 34:66)等度洗脱, 得到化合物**4** ($t_R = 44.6$ min, 3.2 mg)。D4-3 (1.6 g) 经Toyopearl HW-40C凝胶柱色谱分离, 用甲醇进行等度洗脱, 经TLC检识合并相同流分得到5个组分, 即D4-3-1~D4-3-5。D4-3-3 (432.3 mg) 经半制备液相色谱(甲醇-水, 36:64)等度洗脱, 得到化合物**2** ($t_R = 40.6$ min, 8.0 mg)。D4-3-5 (131.1 mg) 经半制备液相色谱(甲醇-水, 35:65)等度洗脱, 得到化合物**8** ($t_R = 37.6$ min, 4.1 mg)。D4-4 (3.5 g) 经Toyopearl HW-40C凝胶柱色谱分离, 用甲醇进行等度洗脱, 经TLC检识合并相同流分得到4个组分, 即D4-4-1~D4-4-4。D4-4-4 (1.9 g) 经硅胶柱色谱分离, 用二氯甲烷-甲醇(30:1→1:1)进行梯度洗脱, 通过TLC检识合并相同流分得到5个组分, 即D4-4-4-1~D4-4-4-5。D4-4-4-2 (310.3 mg) 经半制备液相色谱(甲醇-水, 46:54)等度洗脱, 得到化合物**10** ($t_R = 30.4$ min, 4.2 mg)。D4-4-4-3 (523.6 mg) 经半制备液相色谱(乙腈-水, 17:83)等度洗脱, 得到化合物**9** ($t_R = 37.0$ min, 50.6 mg)。D4-6 (5.2 g) 经Toyopearl HW-40C凝胶柱色谱分离, 用甲醇-水(60:40)进行等度洗脱, 经TLC检识合并相同流分得到4个组分, 即D4-6-1~D4-6-4。D4-6-4 (835.7 mg) 经半制备液相色谱(乙腈-水, 17:83)等度洗脱, 得到化合物**6** ($t_R = 30.4$ min, 6.0 mg)。D4-6-4-4 (71.3 mg) 经半制备液相色谱(乙腈-水, 20:80)等度洗脱, 得到化合物**11** ($t_R = 46.0$ min, 3.2 mg)。D4-7 (4.3 mg) 经Sephadex LH-20凝胶柱色谱分离, 用甲醇-水(60:40)进行等度洗脱, 经TLC检识合并相同流分得到4个组分, 即D4-7-1~D4-7-4。D4-7-1 (620.3 mg) 经半制备液相色谱(乙腈-水, 17:83)等度洗脱, 得到化合物**3** ($t_R = 21.0$ min, 3.1 mg)。D4-7-2 (806.3 mg) 经半制备液相色谱(乙腈-水, 13:87)等度洗脱, 得到化合物**7** ($t_R = 39.0$ min, 5.6 mg)。

2 结构鉴定

化合物**1** 黄色油状物, 易溶于甲醇, $[\alpha]_D^{20} + 89.196$ (c 0.084, CH₃OH); UV (CH₃OH) λ_{max} (log ϵ): 202 (3.65); IR ν_{max} : 1 793, 1 246, 1 158, 1 030 cm⁻¹, HR-ESI-MS m/z : 283.117 6 [M+H]⁺ (计算值为283.117 6); ¹H NMR (500 MHz, DMSO-*d*₆) 和 ¹³C NMR (125 MHz, DMSO-*d*₆) 数据见表1。

Table 1 ¹H NMR (500 MHz) and ¹³C NMR (125 MHz) data of compound **1** in DMSO-*d*₆

No.	δ_H (J in Hz)	δ_C	No.	δ_H (J in Hz)	δ_C
1a	4.40, dd (12.5, 4.0)	66.5	9	3.18, m	44.5
1b	4.35, m		10a	4.65, m	60.5
3	-	172.6	10b	4.61, d (13.5)	
4	3.28, m	40.6	11a	4.30, dd (11.5, 6.0)	61.1
5	3.12, m	33.9	11b	4.03, dd (11.5, 7.5)	
6a	2.42, m	34.3	12	-	170.2
6b	1.90, m		13	2.03, s	20.3
7	5.71, s	129.9	14	-	170.1
8	-	137.1	15	2.03, s	20.3

化合物**2** 白色无定形粉末, 易溶于甲醇, ESI-MS m/z 383 [M+Na]⁺, 分子式为C₂₀H₂₄O₆。 ¹H NMR (500 MHz, CD₃OD) δ_H : 6.95 (1H, d, $J = 2.0$ Hz, H-2), 6.83 (1H, dd, $J = 8.0, 2.0$ Hz, H-6), 6.76 (1H, d, $J = 8.0$ Hz, H-5), 6.73 (2H, s, H-2', 6'), 5.49 (1H, d, $J = 6.5$ Hz, H-7), 3.85 (3H, s, 3'-OMe), 3.84 (1H, m, H-9a), 3.81 (3H, s, 3-OMe), 3.75 (1H, m, H-9b), 3.57 (2H, t, $J = 6.5$ Hz, H-9'), 3.47 (1H, t, $J = 6.0$ Hz, H-8), 2.62 (2H, m, H-7'), 1.81 (2H, m, H-8'); ¹³C NMR (125 MHz, CD₃OD) δ_C : 134.8 (C-1), 110.5 (C-2), 149.1 (C-3), 147.5 (C-4), 116.1 (C-5), 119.7 (C-6), 88.9 (C-7), 55.4 (C-8), 65.0 (C-9), 136.33 (C-1'), 114.1 (C-2'), 145.2 (C-3'), 147.5 (C-4'), 129.9 (C-5'), 117.9 (C-6'), 32.9 (C-7'), 35.8 (C-8'), 62.2 (C-9'), 56.7 (3-OMe), 56.4 (3'-OMe)。以上数据与文献^[10]对比, 确定化合物**2**为(7*S*, 8*R*)-dihydrodehydrodiconiferyl alcohol。

化合物**3** 白色无定形粉末, 易溶于甲醇, ESI-MS m/z 545 [M+Na]⁺, 分子式为C₂₆H₃₄O₁₁。 ¹H NMR (500 MHz, CD₃OD) δ_H : 7.14 (1H, d, $J = 8.0$ Hz, H-5), 7.03 (1H, d, $J = 2.0$ Hz, H-2), 6.93 (1H, dd, $J = 8.0, 2.0$ Hz, H-6), 6.74 (1H, s, H-6'), 6.72 (1H, s, H-2'), 5.56 (1H, d, $J = 5.8$ Hz, H-7), 4.89 (1H, d, $J = 7.0$ Hz, H-1''), 3.86 (3H, s, 3-OMe), 3.83 (3H, s, 3'-OMe), 3.75 (1H, dd, $J = 11.0, 7.5$ Hz, H-9a), 3.68 (1H, dd, $J = 11.0, 4.0$ Hz, H-6''a), 3.57 (2H, t, $J = 6.5$ Hz, H-9'), 3.50 (1H, m, H-9b), 3.45 (1H, m, H-8), 3.40 (1H, m, H-6''b), 3.33 (1H, m, H-5''), 3.28 (1H, m, H-4''), 3.25 (1H, m, H-3''),

3.16 (1H, m, H-2''), 2.62 (2H, t, $J = 8.0$ Hz, H-7'), 1.81 (2H, m, H-8'); ^{13}C NMR (125 MHz, CD_3OD) δ_{C} : 129.6 (C-1), 114.2 (C-2), 145.2 (C-3), 147.6 (C-4), 137.1 (C-5), 117.9 (C-6), 32.9 (C-7), 35.8 (C-8), 62.2 (C-9), 138.3 (C-1'), 111.1 (C-2'), 147.5 (C-3'), 150.9 (C-4'), 118.0 (C-5'), 119.4 (C-6'), 88.4 (C-7'), 55.7 (C-8'), 65.0 (C-9'), 102.7 (C-1''), 74.9 (C-2''), 78.2 (C-3''), 71.3 (C-4''), 77.8 (C-5''), 62.5 (C-6''), 56.7 (3'-OMe), 56.7 (3'-OMe)。以上数据与文献^[11]对比, 确定化合物**3**为 urolignoside。

化合物**4** 黄色油状物, 易溶于甲醇, ESI-MS m/z 331 $[\text{M}+\text{H}]^+$, 分子式为 $\text{C}_{18}\text{H}_{18}\text{O}_6$ 。 ^1H NMR (500 MHz, CD_3OD) δ_{H} : 9.76 (1H, s, H-7'), 7.52 (1H, s, H-2'), 7.46 (1H, s, H-6'), 6.95 (1H, d, $J = 2.0$ Hz, H-2), 6.84 (1H, dd, $J = 8.0, 2.0$ Hz, H-6), 6.79 (1H, d, $J = 8.0$ Hz, H-5), 5.66 (1H, d, $J = 6.5$ Hz, H-7), 3.93 (3H, s, 5'-OMe), 3.87 (2H, m, H-9), 3.82 (3H, s, 3-OMe), 3.61 (1H, m, H-8); ^{13}C NMR (125 MHz, CD_3OD) δ_{C} : 133.6 (C-1), 110.6 (C-2), 149.2 (C-3), 147.9 (C-4), 116.3 (C-5), 119.8 (C-6), 90.6 (C-7), 54.3 (C-8), 64.4 (C-9), 132.7 (C-1'), 122.3 (C-2'), 131.2 (C-3'), 155.6 (C-4'), 146.3 (C-5'), 113.8 (C-6'), 192.7 (C-7'), 56.4 (3-OMe), 56.7 (5'-OMe)。以上数据与文献^[12]对比, 确定化合物**4**为 ficusal。

化合物**5** 黄色油状物, 易溶于甲醇, ESI-MS m/z 445 $[\text{M}+\text{H}]^+$, 分子式为 $\text{C}_{24}\text{H}_{28}\text{O}_8$ 。 ^1H NMR (500 MHz, CD_3OD) δ_{H} : 6.95 (1H, d, $J = 2.0$ Hz, H-2), 6.83 (1H, dd, $J = 8.1, 2.0$ Hz, H-6), 6.78 (1H, d, $J = 8.1$ Hz, H-5), 6.75 (1H, s, H-2'), 6.71 (1H, s, H-6'), 5.44 (1H, d, $J = 7.0$ Hz, H-7), 4.41 (1H, dd, $J = 11.0, 5.5$ Hz, H-9a), 4.32 (1H, dd, $J = 11.0, 7.5$ Hz, H-9b), 4.06 (2H, t, $J = 6.5$ Hz, H-9'), 3.86 (3H, s, 3'-OMe), 3.82 (3H, s, 3-OMe), 3.71 (1H, m, H-8), 2.65 (2H, t, $J = 7.5$ Hz, H-7'), 2.03 (3H, s, 10'-OMe), 1.99 (3H, s, 10'-OMe), 1.94 (2H, m, H-8'); ^{13}C NMR (125 MHz, CD_3OD) δ_{C} : 133.9 (C-1), 110.6 (C-2), 149.2 (C-3), 147.7 (C-4), 116.2 (C-5), 120.1 (C-6), 89.6 (C-7), 51.9 (C-8), 66.7 (C-9), 172.6 (C-10), 20.7 (C-11), 136.4 (C-1'), 114.4 (C-2'), 145.4 (C-3'), 147.8 (C-4'), 128.9 (C-5'), 117.7 (C-6'), 32.9 (C-7'), 31.7 (C-8'), 64.9 (C-9'), 173.0 (C-10'), 20.8 (C-11'), 56.4 (3-OMe), 56.7 (3'-OMe)。以上数据与文献^[13]对比, 确定化合物**5**为 tiruneesiin。

化合物**6** 无色无定形粉末, 易溶于甲醇, ESI-MS m/z 521 $[\text{M}-\text{H}]^-$, 分子式为 $\text{C}_{26}\text{H}_{34}\text{O}_{11}$ 。 ^1H NMR (500 MHz, CD_3OD) δ_{H} : 6.95 (1H, d, $J = 2.0$ Hz, H-2), 6.83 (1H, dd, $J = 8.0, 2.0$ Hz, H-6), 6.77 (1H, d, $J = 8.0$ Hz, H-5), 6.75 (2H, s, H-2', H-6'), 5.49 (1H, d, $J =$

6.5 Hz, H-7), 4.26 (1H, m, H-1''), 3.90 (1H, m, H-9'a) 3.87 (1H, m, H-6''a), 3.85 (3H, s, 3'-OMe), 3.83 (1H, m, H-9a), 3.81 (3H, s, 3-OMe), 3.76 (1H, m, H-9b), 3.66 (1H, m, H-6''b), 3.54 (1H, m, H-9'b), 3.47 (1H, m, H-8), 3.36 (1H, m, H-3''), 3.29 (1H, m, H-4''), 3.26 (1H, m, H-5''), 3.20 (1H, m, H-2''), 2.68 (2H, t, $J = 7.5$ Hz, H-7'), 1.90 (2H, m, H-8'); ^{13}C NMR (125 MHz, CD_3OD) δ_{C} : 134.8 (C-1), 110.5 (C-2), 149.1 (C-3), 147.5 (C-4), 116.1 (C-5), 119.7 (C-6), 89.0 (C-7), 55.5 (C-8), 65.0 (C-9), 136.8 (C-1'), 114.2 (C-2'), 145.2 (C-3'), 147.5 (C-4'), 129.8 (C-5'), 118.1 (C-6'), 32.9 (C-7'), 32.9 (C-8'), 70.0 (C-9'), 104.5 (C-1''), 75.2 (C-2''), 78.1 (C-3''), 71.7 (C-4''), 77.9 (C-5''), 62.8 (C-6''), 56.4 (3-OMe), 56.8 (3'-OMe)。以上数据与文献^[14]对比, 确定化合物**6**为 glochidioboside。

化合物**7** 黄色无定形粉末, 易溶于甲醇, ESI-MS m/z 559 $[\text{M}+\text{Na}]^+$, 分子式为 $\text{C}_{26}\text{H}_{32}\text{O}_{12}$ 。 ^1H NMR (500 MHz, CD_3OD) δ_{H} : 7.69 (1H, d, $J = 8.5, 2.0$ Hz, H-6), 7.66 (1H, dd, $J = 2.0$ Hz, H-2), 7.26 (1H, d, $J = 8.5$ Hz, H-5), 7.05 (1H, d, $J = 1.8$ Hz, H-2'), 6.84 (1H, d, $J = 8.0, 1.8$ Hz, H-6'), 6.76 (1H, d, $J = 8.0$ Hz, H-5'), 5.06 (1H, d, $J = 7.5$ Hz, H-1''), 4.64 (1H, d, $J = 8.5$ Hz, H-7'), 4.27 (1H, m, H-8), 4.19 (1H, m, H-9a), 4.17 (1H, m, H-9b), 3.93 (3H, s, 3-OMe), 3.91 (1H, m, H-6''a), 3.88 (3H, s, 3'-OMe), 3.67 (1H, m, H-6''b), 3.64 (2H, m, H-9'a), 3.55 (1H, m, H-2''), 3.51 (1H, m, H-5''), 3.48 (1H, m, H-3''), 3.42 (1H, m, H-4''), 2.69 (1H, m, H-8'); ^{13}C NMR (125 MHz, CD_3OD) δ_{C} : 132.4 (C-1), 113.0 (C-2), 150.8 (C-3), 152.5 (C-4), 116.3 (C-5), 124.3 (C-6), 200.4 (C-7), 50.5 (C-8), 71.6 (C-9), 133.5 (C-1'), 111.4 (C-2'), 149.1 (C-3'), 147.5 (C-4'), 115.8 (C-5'), 121.0 (C-6'), 85.3 (C-7'), 54.6 (C-8'), 61.4 (C-9'), 101.8 (C-1''), 74.7 (C-2''), 78.4 (C-3''), 71.2 (C-4''), 77.8 (C-5''), 62.4 (C-6''), 56.7 (3-OMe), 56.4 (3'-OMe)。以上数据与文献^[15]对比, 确定化合物**7**为 forsythialansides B。

化合物**8** 黄色无定形粉末, 易溶于甲醇, ESI-MS m/z 373 $[\text{M}+\text{Na}]^+$, 分子式为 $\text{C}_{20}\text{H}_{22}\text{O}_7$ 。 ^1H NMR (500 MHz, CD_3OD) δ_{H} : 7.62 (1H, overlapped, H-6), 7.61 (1H, overlapped, H-2), 7.06 (1H, d, $J = 2.0$ Hz, H-2'), 6.88 (1H, d, $J = 8.5$ Hz, H-5), 6.85 (1H, d, $J = 8.0, 2.0$ Hz, H-6'), 6.76 (1H, d, $J = 8.0$ Hz, H-5'), 4.64 (1H, d, $J = 9.0$ Hz, H-7'), 4.26 (1H, m, H-8), 4.19 (1H, t, $J = 8.5$ Hz, H-9a), 4.15 (1H, dd, $J = 8.5, 5.5$ Hz, H-9b), 3.92 (3H, s, 3-OMe), 3.88 (3H, s, 3'-OMe), 3.65 (1H, m, H-9'a), 3.60 (1H, m, H-9'b), 2.69 (1H, m, H-8'); ^{13}C NMR

(125 MHz, CD₃OD) δ_c : 129.8 (C-1), 112.4 (C-2), 154.1 (C-3), 149.3 (C-4), 116.0 (C-5), 125.1 (C-6), 200.3 (C-7), 50.2 (C-8), 61.2 (C-9), 133.5 (C-1'), 111.4 (C-2'), 149.1 (C-3'), 147.5 (C-4'), 115.8 (C-5'), 121.0 (C-6'), 85.3 (C-7'), 54.6 (C-8') 71.8 (C-9'), 56.4 (3-OMe), 56.3 (3'-OMe)。以上数据与文献^[16]对比, 确定化合物 **8** 为 ecdysanol B。

化合物 **9** 无色无定形粉末, 溶于甲醇, $[\alpha]_D^{20} +9.485$ (*c* 0.2, CH₃OH); ESI-MS *m/z* 579 [M-H]⁻, 分子式为 C₂₈H₃₆O₁₃。¹H NMR (500 MHz, DMSO-*d*₆) δ_H : 8.27 (1H, s, 4'-OH), 6.65 (2H, s, H-2, 6), 6.59 (2H, s, H-2', 6'), 4.88 (1H, m, H-1''), 4.66 (1H, d, *J* = 4.5 Hz, H-7'), 4.93~4.15 (4H, m, 2'', 3'', 4'', 6''-OH), 4.61 (1H, dd, *J* = 4.5 Hz, H-7), 4.26 (1H, m, H-9a), 4.17 (1H, m, H-9b), 4.167 (1H, m, H-9'a), 3.81 (1H, m, H-9'b), 3.76 (6H, s, 3', 5'-OMe), 3.75 (6H, s, 3, 5-OMe), 3.81-3.19 (6H, m, H-2'', 3'', 4'', 6''); ¹³C NMR (125 MHz, DMSO-*d*₆) δ_c : 133.7 (C-1), 104.2 (C-2), 152.7 (C-3, 5), 134.9 (C-4), 104.2 (C-6), 85.2 (C-7), 53.8 (C-8), 71.2 (C-9), 131.4 (C-1'), 103.7 (C-2', 6'), 147.9 (C-3', 5'), 137.3 (C-4'), 85.4 (C-7'), 53.7 (C-8'), 71.3 (C-9'), 102.7 (C-1''), 74.2 (C-2''), 76.6 (C-3''), 70.0 (C-4''), 77.3 (C-5''), 60.9 (C-6''), 56.5 (3, 5-OMe), 56.1 (3', 5'-OMe)。以上数据与文献^[17]对比, 确定化合物 **9** 为 (+)-syringaresinol-4-*O*- β -D-glucopyranoside。

化合物 **10** 无色无定形粉末, 易溶于甲醇, $[\alpha]_D^{20} +15.359$ (*c* 0.4, CH₃OH); ESI-MS *m/z* 693 [M+Na]⁺, 分子式为 C₃₄H₃₈O₁₄。¹H NMR (500 MHz, CD₃OD) δ_H : 7.82 (1H, dd, *J* = 8.0, 1.9 Hz, H-6'), 7.58 (1H, dd, *J* = 8.5, 1.9 Hz, H-6'''), 7.54 (1H, d, *J* = 1.9 Hz, H-2'''), 6.98 (1H, d, *J* = 1.9 Hz, H-2'), 6.97 (1H, overlapped, H-5), 6.95 (1H, overlapped, H-2), 6.87 (1H, d, *J* = 8.5 Hz, H-5'''), 6.78 (1H, d, *J* = 8.0 Hz, H-5'), 6.44 (1H, dd, *J* = 8.5, 2.0 Hz, H-6), 4.87 (1H, overlapped, H-1''), 4.67 (2H, m, H-7, 7'), 4.63 (1H, m, H-6''a), 4.46 (1H, m, H-6''b), 4.24 (2H, dd, *J* = 9.0, 7.2 Hz, H-9a, 9'a), 3.87 (3H, s, 3'-OMe), 3.83 (6H, s, 3', 3'''-OMe), 3.82 (1H, m, H-9'b), 3.80 (1H, m, H-9b), 3.76 (1H, m, H-5''), 3.54 (1H, m, H-2''), 3.49 (1H, m, H-3''), 3.41 (1H, t, *J* = 9.5 Hz, H-4''), 3.08 (1H, m, H-8'), 2.98 (1H, m, H-8); ¹³C NMR (125 MHz, CD₃OD) δ_c : 137.4 (C-1), 111.6 (C-2), 150.7 (C-3), 147.1 (C-4), 117.7 (C-5), 119.3 (C-6), 87.0 (C-7), 55.4 (C-8), 72.8 (C-9), 133.7 (C-1'), 111.0 (C-2'), 149.1 (C-3'), 147.3 (C-4'), 116.1 (C-5'), 120.2 (C-6'), 87.6 (C-7'), 55.3 (C-8'), 72.5 (C-9'), 102.4 (C-1''), 74.8 (C-2''),

77.8 (C-3''), 72.2 (C-4''), 75.6 (C-5''), 65.0 (C-6''), 122.5 (C-1'''), 113.9 (C-2'''), 148.8 (C-3'''), 153.0 (C-4'''), 116.0 (C-5'''), 125.3 (C-6'''), 167.7 (C-7'''), 56.7 (3-OMe), 56.4 (3'-OMe), 56.5 (3'''-OMe)。以上数据与文献^[18]对比, 确定化合物 **10** 为 (+)-pinoresinol-4-*O*-[6''-*O*-vanilloyl]- β -D-glucopyranoside。

化合物 **11** 黄色无定形粉末, 易溶于甲醇, ESI-MS *m/z* 769 [M+Na]⁺, 分子式为 C₃₇H₄₆O₁₆。¹H NMR (500 MHz, CD₃OD) δ_H : 7.09 (1H, d, *J* = 8.5 Hz, H-5''), 7.04 (1H, d, *J* = 2.0 Hz, H-2''), 6.95 (1H, d, *J* = 2.0 Hz, H-2), 6.89 (1H, dd, *J* = 8.5, 2.0 Hz, H-6''), 6.81 (1H, dd, *J* = 8.0, 2.0 Hz, H-6), 6.78 (1H, d, *J* = 8.0 Hz, H-5), 6.66 (2H, s, H-2', 6'), 4.91 (1H, d, *J* = 6.0 Hz, H-7''), 4.88 (1H, overlapped, H-1'''), 4.74 (1H, d, *J* = 4.0 Hz, H-7'), 4.71 (1H, m, H-7), 4.29 (1H, m, H-8''), 4.27 (2H, m, H-9), 3.89 (1H, m, H-9'a), 3.87 (2H, m, H-9'), 3.86 (3H, s, 3''-OMe), 3.83 (3H, s, 3-OMe), 3.81 (6H, s, 3', 5'-OMe), 3.84 (1H, m, H-6'''a), 3.68 (1H, m, H-6'''b), 3.60 (1H, m, H-9'b), 3.47 (1H, m, H-2'''), 3.45 (1H, m, H-5'''), 3.41 (1H, m, H-4'''), 3.38 (1H, m, H-3'''), 3.14 (2H, m, H-8, H-8'); ¹³C NMR (125 MHz, CD₃OD) δ_c : 133.7 (C-1), 110.1 (C-2), 149.1 (C-3), 147.3 (C-4), 116.1 (C-5), 120.0 (C-6), 87.4 (C-7), 55.3 (C-8), 72.9 (C-9), 138.9 (C-1'), 104.2 (C-2', 6'), 154.4 (C-3', 5'), 136.0 (C-4'), 87.3 (C-7'), 55.7 (C-8'), 72.7 (C-9'), 137.3 (C-1''), 112.3 (C-2''), 150.3 (C-3''), 147.2 (C-4''), 117.2 (C-5''), 120.9 (C-6''), 73.8 (C-7''), 86.9 (C-8''), 62.5 (C-9''), 102.7 (C-1'''), 74.9 (C-2'''), 78.2 (C-3'''), 71.4 (C-4'''), 77.8 (C-5'''), 61.7 (C-6'''), 56.7 (3, 3'-OMe), 56.6 (5''-OMe), 56.4 (3''-OMe)。以上数据与文献^[19]对比, 确定化合物 **11** 为 samsesquinoside。

作者贡献: 周诗琪为本文第一作者, 负责化合物的分离、鉴定和文章撰写; 杨梦、肖超远、张俊阳、张博文、陶思琦对提取分离和结构鉴定提供了一定帮助; 郝志友博士对实验中遇到的问题给予指导并负责相关稿件的修改; 郑晓珂教授和冯卫生教授负责实验设计、稿件修改等工作。

利益冲突: 所有作者均声明不存在利益冲突。

References

- [1] Feng H, Zhou HH, Ouyang DS. Chemical constituents and pharmacology of *Eucommia ulmoides* Oliv [J]. Chin J Clin Pharm Ther (中国临床药理学与治疗学), 2015, 20: 713-720.
- [2] Li K, Hao ZY, Zhang CL. Chemical constituents from *Eucommia ulmoides* [J]. J Chin Med Mater (中药材), 2016, 39: 2016-2018.
- [3] Zhang M, Liang FN, Sun YW, et al. Research progress on chemi-

- cal constituents, pharmacological effects and clinical application of *Eucommia ulmoides* [J]. Chin Tradit Herb Drugs (中草药), 2023, 54: 4740-4761.
- [4] Xing YF, He D, Wang Y, et al. Chemical constituents, biological functions and pharmacological effects for comprehensive utilization of *Eucommia ulmoides* Oliver [J]. Food Sci Hum Wellness, 2019, 8: 177-188.
- [5] Xiang Z, Li HJ, Shen XY, et al. Research progress on chemical constituents, pharmacological effects and product development of *Eucommia ulmoides*: a medicinal and edible plant with dual purposes [J]. Chin J Exp Tradit Med Formulae (中国实验方剂学杂志), 2023, 24: 77-82.
- [6] Liu ZZ. Chemical Constituents of *Thesium chinense* Turcz and *in vitro* Activity Studies (百蕊草化学成分及体外活性研究) [D]. Hefei: Anhui Medical University, 2023.
- [7] Wu JJ, Huang HX, Li WC, et al. Study on chemical constituents and anti-inflammatory activity of the pomace of *Siraita grosvenorii* [J]. Nat Prod Res Dev (天然产物研究与开发), 2023, 35: 1124-1134.
- [8] Lee H, Choi H, Ko HJ, et al. Antifungal effect and mode of action of glochidioboside against *Candida albicans* membranes [J]. Biochem Bioph Res Commun, 2014, 444: 30-35.
- [9] Nguyen KDH, Dang PH, Nguyen HX, et al. Phytochemical and cytotoxic studies on the leaves of *Calotropis gigantea* [J]. Bioorg Med Chem Lett, 2017, 27: 2902-2906.
- [10] Deng AJ, Zhang HJ, Zhang ZH, et al. Constituents with anti-oxidative activity from seeds of Jufeng grape [J]. China J Chin Mater Med (中国中药杂志), 2015, 40: 4208-4211.
- [11] Hu RH, Yin X, Zhou YQ, et al. Chemical constituents from the root of *Ardisia crispa* (Thumb.) A DC [J]. Chin Pharm J (中国药学杂志), 2022, 57: 605-612.
- [12] Hu RH, Yin X, Zhou YQ, et al. Four new compounds, fical, ficesquiliglan A, B, and ficosolide diacetate from the heartwood of *Ficus microcarpa* [J]. Chem Pharm Bull, 2000, 48: 1862-1865.
- [13] Gopalaiah K, Jakka K, Raju VK, et al. Justicia lignans: part 9-two new lignans from *Justicia neesii* Ramamoorthy (white flower variety) [J]. Indian J Chem Sect B, 2001, 40: 596-600.
- [14] Dong LP, Ni W, Dong JY, et al. A new neolignan glycoside from the leaves of *Acer truncatum* [J]. Molecules, 2006, 11: 1009-1014.
- [15] Li C, Dai Y, Zhang SX, et al. Quinoid glycosides from *Forsythia suspensa* [J]. Phytochemistry, 2014, 104: 105-133.
- [16] Dong DD, Li H, Jiang K, et al. Diverse lignans with anti-inflammatory activity from *Urceola rosea* [J]. Fitoterapia, 2019, 134: 96-100.
- [17] Tang J, Ma RL, Ouyang Z, et al. Chemical constituents from the water-soluble fraction of wild *Sargentodoxa cuneata* [J]. Chin J Nat Med (中国天然药物), 2012, 10: 115-118.
- [18] Parhira S, Yang ZF, Zhu GY, et al. *In vitro* anti-influenza virus activities of a new lignan glycoside from the latex of *Calotropis gigantea* [J]. PLoS One, 2014, 9: e104544.
- [19] Xiao HH, Dai Y, Wong MS, et al. New lignans from the bioactive fraction of *Sambucus williamsii* hance and proliferation activities on osteoblastic-like UMR106 cells [J]. Fitoterapia, 2014, 94: 29-35.